Resumo

REYES-MARTINEZ, Viviana et al. Mesenchymal stromal cells represent a therapeutic option for systemic sclerosis patients. Rev.Colomb.Reumatol. [online]. 2020, vol.27, suppl.1, pp.126-134.  Epub 23-Ago-2021. ISSN 0121-8123.  https://doi.org/10.1016/j.rcreu.2020.02.007.

The mesenchymal stromal cells (MSCs) are hematopoietic stem cells with high capacity of differentiation to other cellular lineages, depending on the microenvironment in which they live as well as on the interaction and signaling pathways they establish with the extracellular matrix. Several properties have been described in these cells: proangiogenic, antifibrotic and immunomodulatory. These properties are being studied as a therapeutic approach for autoimmune diseases such as cutaneous systemic sclerosis (SSc). SSc is a systemic chronic disease, with an approximate prevalence of 35.6 cases per 100,000 inhabitants in North America and of 0.02% in Colombia in 2018. There are two different clinical variants, diffuse and localized. In both variants an important skin involvement and a rapidly deterioration of organs is present, which can overshadow the clinical prognosis and increase the mortality. Options for the treatment of advanced diffuse SSc are scarce mainly targeting symptomatic control with little impact on the progression and mortality. Therefore, there is an increasing interest in new therapies like advanced cellular therapy with hematopoietic stem cells and stromal mesenchymal cells. This article reviews the information related to the use of stromal mesenchymal cells in patients with this disease.

Palavras-chave : Mesenchymal stromal cells; Diffuse systemic sclerosis; Limited systemic sclerosis; Hematopoietic stem cells; Advanced cell therapy.

        · resumo em Espanhol     · texto em Inglês | Espanhol     · Inglês ( pdf ) | Espanhol ( pdf )